Sunshine Heart Announces CE Mark for C-Pulse(R) Heart Assist System

Sunshine Heart, Inc. (SSH) (SHC.AX) announced today that it has received CE Mark approval for its C-Pulse Heart Assist System for the treatment of Class III and ambulatory Class IV heart failure. This will allow for commercialization of the technology in Europe and countries in Asia and Latin America that recognize the CE Mark. The Class III heart failure population is estimated at 3.7 million patients in the European Union, and currently, there are limited, and often, unsuccessful treatment options for this patient population.

Published: 25 July 2012
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Sunshine Heart Inc ( SSH )

Bacterin International Signs Its Fourth National GPO Contract with the Premier healthcare alliance

Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, announces its fourth national GPO (group purchasing organization) contract, a three-year agreement with the Premier healthcare alliance, one of the nations largest GPOs, serving over 2,600 hospitals and more than 84,000 other healthcare sites that represent over $43 billion in annual purchasing power. The agreement provides Bacterin's full biologic portfolio, including OsteoSponge®, OsteoSelect® DBM Putty, OsteoWrap®, OsteoLock®, BacFast®, hMatrix®, Sports Medicine Allografts, and traditional allografts for specially negotiated pricing to the nationwide network of hospitals and medical practices served by Premier. The group purchasing agreement became effective, after performing months of research and evaluation of the Bacterin product lines.

Published: 19 July 2012
Written by Editor
AMEX   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Bacterin International Holdings Inc ( BONE )

pSivida Corp. Announces France Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema

pSivida Corp. (PSDV) (PVA.AX), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Security Agency of Medicines and Health Products (L’Agence Nationale de Sécurité du Médicament et des Produits de Santé) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Published: 19 July 2012
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: pSivida Corp ( PSDV )

Tegal Corporation to Acquire CollabRx, Inc.

Brings Interpretive Content and Data Analytics to Genomics-Based Medicine

Tegal Corporation (TGAL) today announced that it has signed a definitive agreement to acquire CollabRx, Inc., a privately held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine.

CollabRx offers cloud-based expert systems that provide clinically relevant interpretive knowledge to institutions, physicians, researchers and patients for genomics-based medicine in cancer and other diseases to inform health care decision making. With access to approximately 50 clinical and scientific advisors at leading academic institutions and a suite of tools and processes that combine artificial intelligence-based analytics with proprietary interpretive content, the company is well positioned to participate in the $300 billion value-added “big data” opportunity in the US health care market (as reported by McKinsey Global Institute), over half of which specifically targets areas in cancer and cancer genomics.1

Published: 02 July 2012
Written by Editor
Nasdaq   Healthcare   M & A   Up on News   Interesting News  
Read more: Tegal Corporation ( TGAL )

FDA Panel Recommends Approval of Edwards Transcatheter Valve for High-Risk Patients

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that a U.S. Food and Drug Administration (FDA) Advisory Panel voted in favor of recommending approval of the Edwards SAPIEN transcatheter heart valve via transfemoral and transapical delivery for the treatment of high-risk patients with severe, symptomatic aortic stenosis. The panel voted 11 to 0, with one abstention, that the benefits of the heart valve outweighed the risks for these patients.

Published: 14 June 2012
Written by Editor
NYSE   Healthcare   FDA HC Decision   Up on News   Interesting News  
Read more: Edwards Lifesciences Corporation ( EW )
  1. Medgenics Inc ( MDGN )
  2. Kensey Nash Corporation ( KNSY )
  3. Conceptus, Inc ( CPTS )
  4. Align Technology Inc ( ALGN )
  5. TSO3 Inc ( TOS )